Saint Louis, Missouri 63110

  • Acute Myeloid Leukemia


This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from <10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (>60% any grades or >30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).


Recipient Inclusion Criteria: - Refractory AML without complete remission (CR) after 2 or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one or more cycles of re-induction therapy. Standard dose 10-day decitabine (20 mg/m2 daily IV x 10 days) or 7-day azacitidine (75-100 mg/m2 daily SC/IV x 7 days) will be considered as one cycle of induction therapy. - At least 18 years of age - Deemed to be not otherwise eligible for a non-myeloablative hematopoietic cell transplant by the treating physician. - Available HLA-haploidentical donor that meets the criteria in the protocol - Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment. - Karnofsky performance status > 60 % - Adequate organ function as defined below: - Total bilirubin < 2 mg/dl - AST(SGOT)/ALT(SGPT) < 3.0 x IULN - Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m2 by Cockcroft-Gault Formula - Oxygen saturation ≥90% on room air and adjusted DLCO of at least 40% - Ejection fraction ≥40% - Able to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on Day -3 - Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the DLT evaluation period. - Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Recipient Exclusion Criteria: - Relapsed after allogeneic transplantation. - Circulating blast count >30,000/uL by morphology or flow cytometry (cyto-reductive therapies including leukapheresis or hydroxyurea are allowed). - Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection. - Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of >5000 as assessed by the single antigen bead assay, < 6 weeks prior to starting transplant conditioning - Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities. - New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections) - Known hypersensitivity to one or more of the study agents - Received any investigational drugs within the 14 days prior to the first day of transplant conditioning - Pregnant and/or breastfeeding Donor Inclusion Criteria: - Related donor (sibling, offspring, or offspring of sibling) - At least 18 years of age - HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus. - In general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study. - Ability to understand and willingness to sign an IRB approved written informed consent document Donor Exclusion Criteria: - Positive for hepatitis, HTLV, or HIV infection - Pregnant and/or breastfeeding



Primary Contact:

Principal Investigator
Amanda Cashen, M.D.
Washington University School of Medicine

Amanda Cashen, M.D.
Phone: (314) 454-8323

Backup Contact:


Location Contact:

Saint Louis, Missouri 63110
United States

Amanda Cashen, M.D.
Phone: 314-454-8323

Site Status: Recruiting

Data Source:

Date Processed: July 30, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.